Publication

Article

Cardiology Review® Online

November 2007
Volume24
Issue 11

Increased creatine-kinase MB level after bypass surgery

A 72-year-old man presented with angina, dynamic ST-segment depression, and increased troponin and creatine kinase-myocardial band (CK-MB) levels above the institutional upper limits of normal (ULN).

A 72-year-old man presented with angina, dynamic ST-segment depression, and increased troponin and creatine kinase-myocardial band (CK-MB) levels above the institutional upper limits of normal (ULN). Initial medical therapy included aspirin, antithrombin therapy, beta blockers, angiotensin-converting enzyme (ACE) inhibitors, and glycoprotein IIb/IIIa inhibitors.

The patient underwent coronary angiography, which showed 3-vessel coronary artery disease. Three days later, he underwent coronary artery bypass graft (CABG) surgery with no complications. Prior to surgery, his CK-MB level had returned to normal, but when his CK-MB level was checked the day after surgery, it was 58 (ULN x 9). He had an uneventful postoperative course and was treated with aspirin, a beta blocker, an ACE inhibitor, and a statin. Based on the results of our study, the patient's increased post-CABG surgery CK-MB level was an independent predictor of worse mortality over the 6-month follow-up period. It is not yet known how to best treat patients specifically for CK-MB elevation, but prudent care would include aggressive secondary prevention. More research is needed to develop agents and strategies for myocardial preservation during CABG surgery.

Related Videos
The APAC Recap: Peripheral Artery Disease at CAPP Live 2024 with Bob Ross, PA-C | Image Credit: APAC
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
© 2024 MJH Life Sciences

All rights reserved.